SECsense Logo

Supernus Pharmaceuticals 8-K Report: Key Developments for Investors

$SUPN
Form 8-K
Filed on: 2025-02-24
Source
Supernus Pharmaceuticals 8-K Report: Key Developments for Investors

Here are the key pieces of information extracted from the provided section of the financial report:

  1. Entity Information:
  • Name: Supernus Pharmaceuticals, Inc.
  • CIK Number: 0001356576
  • State of Incorporation: Delaware (DE)
  • IRS Employer Identification Number (EIN): 20-2590184
  • Address: 9715 Key West Ave, Rockville, MD 20850
  • Phone Number: 301-838-2500
  • Stock Ticker: SUPN
  • Exchange: NASDAQ
  1. Filing Information:
  • Filing Type: 8-K
  • Filing Date: February 24, 2025
  • Period Covered: February 24, 2025
  1. Security Information:
  • Type of Security: Common Stock
  • Par Value: $0.001 per share
  1. XBRL Context:
  • The data follows the XBRL format, which is used for electronic financial reporting.

Insights:

  • The report indicates that Supernus Pharmaceuticals, Inc. is filing an 8-K, which is typically used to report major events that shareholders should know about. The timing of the filing suggests that there may be significant developments or announcements about the company on or just before February 24, 2025.
  • The inclusion of specific identifiers (CIK, EIN, stock ticker) and contact information provides clarity on the company's identity and facilitates shareholder inquiries.
  • The report is structured using XBRL, indicating compliance with modern financial reporting standards that enhance transparency and data usability.

This information is crucial for investors, analysts, and stakeholders who are tracking Supernus Pharmaceuticals for any developments that could impact their investment decisions.